Physician profile
Albert Galdi
NPI 1760480917
$15,158.21
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,621 · 2020: $13K · 2021: $24.17 · 2022: $55.10.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $12,746.09 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $733.24 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $458.20 | 2019-2022 | |
| Biogen, INC. | $187.23 | 2019-2020 | |
| Emd Serono, INC. | $170.72 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $121.97 | 2019-2021 | |
| Lundbeck LLC | $117.76 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $99.04 | 2019-2020 | |
| Genentech USA, INC. | $92.02 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $71.51 | 2019 | |
| Mallinckrodt Enterprises LLC | $51.66 | 2019 | |
| Adamas Pharmaceuticals, INC. | $38.80 | 2020 | |
| Genzyme Corporation | $37.95 | 2019 | |
| Kyowa Kirin, INC. | $37.54 | 2020 | |
| Grifols USA, LLC | $19.50 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $19.35 | 2019 | |
| Vertical Pharmaceuticals, LLC | $17.17 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.12 | 2020 | |
| Avanir Pharmaceuticals, INC. | $16.71 | 2019 | |
| Assertio Therapeutics, INC. | $16.54 | 2020 | |
| Strongbridge US INC. | $16.34 | 2019 | |
| Neurocrine Biosciences, INC. | $15.32 | 2020 | |
| Amneal Pharmaceuticals LLC | $15.06 | 2020 | |
| Amgen INC. | $15.03 | 2019 | |
| Acadia Pharmaceuticals INC | $14.74 | 2019 | |
| Zyla Life Sciences, INC. | $11.60 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Galdi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.